Drug intelligence / Profile preview

AllerT1

Development stage: Preclinical
Modality: Peptides
Administration: Intradermal

Overview

AllerT1 is a synthetic peptide referenced in clinical trials for skin prick testing in subjects allergic to birch. It appears to be used as an investigational agent for allergy diagnostics or research, specifically targeting birch pollen allergy. The mechanism of action is not fully described in available sources, but it is likely designed to mimic allergenic epitopes from birch pollen for diagnostic or desensitization purposes[3]. There is no evidence of therapeutic use beyond research and diagnostic applications.

Other names: synthetic peptide T1AllerT1AllerT-1AllerT 1

Targets

γδ TCR (T-cell receptor)HLA-DR (Human leukocyte antigen DR)

Beyond the preview

Go deeper on AllerT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllerT1.

Explore the full profile